Bacterial Meningococcal Disease: Global Outbreaks and Risks to Students

Recent outbreaks of bacterial meningococcal disease in England and cases among students in New Zealand have highlighted the ongoing risks associated with this life-threatening condition. The disease, caused by the bacterium Neisseria meningitidis, can manifest as meningitis—an inflammation of the membranes covering the brain and spinal cord—or septicaemia, where bacteria enter the bloodstream and affect the entire body.

According to reporting from The Conversation on April 9, 2026, the strains responsible for the outbreaks in England and recent cases in Dunedin, New Zealand, both belong to Group B meningococci. However, research indicates these cases were caused by different strains. The outbreak strain in the United Kingdom is identified as ST485, while the Dunedin cases involved different strains from each other, suggesting multiple chains of transmission were involved.

Infants, children, and young adults are identified as high-risk groups for the disease. In New Zealand, only one vaccine is currently included on the national immunisation schedule.

Rising Incidence in the United States

Parallel to the outbreaks in Europe and Oceania, the United States has seen a sharp increase in meningococcal disease since 2021, with rates now exceeding pre-pandemic levels. Data released by the Centers for Disease Control and Prevention (CDC) on February 24, 2026, indicates that 503 confirmed and probable cases were reported in 2024 based on preliminary data.

This figure represents the highest number of U.S. Meningococcal disease cases reported since 2013. The CDC identifies Neisseria meningitidis serogroup Y as the primary driver of this recent increase, with incidence for this specific serogroup beginning to rise in 2022.

Certain populations in the U.S. Have been disproportionately affected by this increase, including:

• People between the ages of 30 and 60 years
• Black or African American people
• Adults with HIV

Public health officials have advised healthcare providers to maintain a heightened index of suspicion for the disease, particularly among these populations, and to be aware of atypical presentations. Patients with septic arthritis or bloodstream infections may not present with typical meningitis symptoms.

Global Trends and the Meningitis Belt

On a global scale, the highest incidence of meningococcal disease is found in the meningitis belt of sub-Saharan Africa. This region has historically experienced major epidemics every 5 to 12 years, with attack rates reaching up to 1,000 cases per 100,000 people. Favorable conditions for these epidemics include crowded living conditions, travel, large population displacements, and dry, dusty conditions during the dry season from December to June.

The epidemiology of the disease in this region has shifted over time. While outbreaks were historically caused primarily by serogroup A, the introduction of the monovalent serogroup A meningococcal conjugate vaccine (MenAfriVac®) in 2010 changed the landscape. Recent outbreaks in the region are now primarily caused by serogroups C and W, with reports of serogroup X outbreaks as well.

To combat these evolving threats, a new vaccine known as Men5CV (or MenFive) was developed to protect against five serogroups: A, C, W, Y, and X. According to CDC information updated March 16, 2026, this vaccine was first deployed in 2024 in Niger and Nigeria in response to outbreaks in those countries.

Pathogen Characteristics and Prevention

The bacterium Neisseria meningitidis is categorized into six main groups: A, B, C, W, X, and Y. In temperate regions, including Australia, the Americas, and Europe, serogroups B, C, W, and Y account for the vast majority of cases, with an increase in incidence typically observed during the winter and spring.

The bacterium possesses a significant ability to swap genetic material and switch genes on and off through a process called phase variation. This mechanism allows the bacterium to alter its surface, which can enable it to escape the human immune system.

While the disease is largely preventable through vaccination, the specific vaccine requirements vary by region and risk group. Public health agencies continue to monitor the impact of newer vaccines, such as Men5CV, and encourage individuals to stay up to date with the latest vaccination guidance.